References
Falkson G, MacIntyre JM, Moertel CG, Johnson LA, Scherman RC (1984) Primary liver cancer, an Eastern Cooperative Oncology Group trial. Cancer 54:970–977
Johnson PJ, Williams R, Thomas H, Sherlock S, Murray-Lyon IM (1978) Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet 1(8442):1006–1010
Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ (1998) Doxorubicin versus no antitumour therapy in inoperable hepatocellular carcinoma: A prospective randomized trial. Cancer 62:479–483
Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN (1993) Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 4:327–332
Neuman MG (2001) Apoptosis in diseases of the liver. Crit Rev Clin Lab Sci 38(2):109–166
Ghavami S, Hashemi M, Kadkhoda K, Alavian SM, Bay GH, Los M (2005) Apoptosis in liver diseases—detection and therapeutic applications. Med Sci Monit 11:RA337–RA345
Chiu CT, Yeh TS, Hsu JS, Chen MF (2003) Expression of Bcl-2 family modulated through p53-dependent pathway in human hepatocellular carcinoma. Dig Dis Sci 48(4):670–676
Cheng SC, Luo D, Xie Y (2001) Taxol induced Bcl-2 protein phosphorylation in human hepatocellular carcinoma QGY-7703 cell line. Cell Biol Int 25(3):261–265
Luo D, Cheng SC, Xie H, Xie Y (1999) Chemosensitivity of human HCC cell line QGY-7703 is related to bcl-2 protein levels. Tumour Biol 20(6):331–340
Ma S, Lee TK, Zheng BT, Chan KW (2007) CD133(+) HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene (in press)
Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD (2000) Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res 6:2891–2902
Lopes de Menezes DE, Mayer LD (2001) Combination of bcl-2 antisense oligodeoxynucleotide (G3139), p-glycoprotein inhibitor (PSC833) and liposomal doxorubicin can suppress the growth of drug-resistant human breast cancer xenografts in SCID mice “abstract”. Proc Ann Meet Am Assoc Cancer Res 42:A2018
Conflict of interest statement
None declared.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work is supported by an NIH/NCI Phase II Consortium NO-1 Grant 1710701.
Rights and permissions
About this article
Cite this article
Knox, J.J., Chen, X.E., Feld, R. et al. A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798). Invest New Drugs 26, 193–194 (2008). https://doi.org/10.1007/s10637-007-9104-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-007-9104-1